JY
ADMA icon

Jeff Yass’s ADMA Biologics ADMA Stock Holding History

Jeff Yass’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.3M Sell
394,700
-845,500
-68% -$7.71M ﹤0.01% 5428
2026
Q1 		$11.2M Sell
1,240,200
-321,900
-21% -$5.08M ﹤0.01% 2944
2025
Q4 		$28.5M Buy
1,562,100
+489,700
+46% +$8.25M ﹤0.01% 1866
2025
Q3 		$15.7M Buy
1,072,400
+141,800
+15% +$2.43M ﹤0.01% 2460
2025
Q2 		$16.9M Buy
930,600
+109,300
+13% +$2.23M ﹤0.01% 2179
2025
Q1 		$16.3M Sell
821,300
-59,700
-7% -$1.03M ﹤0.01% 1947
2024
Q4 		$15.1M Buy
881,000
+313,600
+55% +$5.9M ﹤0.01% 2157
2024
Q3 		$11.3M Buy
567,400
+154,100
+37% +$2.4M ﹤0.01% 2452
2024
Q2 		$4.62M Buy
413,300
+351,600
+570% +$2.95M ﹤0.01% 3568
2024
Q1 		$407K Buy
61,700
+14,900
+32% +$81.4K ﹤0.01% 8993
2023
Q4 		$212K Sell
46,800
-2,600
-5% -$9.62K ﹤0.01% 10570
2023
Q3 		$177K Sell
49,400
-45,800
-48% -$176K ﹤0.01% 10366
2023
Q2 		$351K Buy
95,200
+4,900
+5% +$18.2K ﹤0.01% 9117
2023
Q1 		$299K Buy
90,300
+11,200
+14% +$38.7K ﹤0.01% 9726
2022
Q4 		$307K Sell
79,100
-51,800
-40% -$160K ﹤0.01% 9045
2022
Q3 		$318K Buy
130,900
+42,500
+48% +$102K ﹤0.01% 9642
2022
Q2 		$175K Buy
88,400
+2,700
+3% +$5.31K ﹤0.01% 10831
2022
Q1 		$157K Buy
85,700
+62,400
+268% +$97.3K ﹤0.01% 11512
2021
Q4 		$33K Sell
23,300
-11,900
-34% -$15.6K ﹤0.01% 12713
2021
Q3 		$40K Sell
35,200
-17,100
-33% -$24K ﹤0.01% 12415
2021
Q2 		$84K Sell
52,300
-12,600
-19% -$22.2K ﹤0.01% 12153
2021
Q1 		$114K Buy
64,900
+21,100
+48% +$48.3K ﹤0.01% 11789
2020
Q4 		$85K Sell
43,800
-84,900
-66% -$178K ﹤0.01% 10574
2020
Q3 		$308K Buy
+128,700
New +$353K ﹤0.01% 8647
2020
Q2 		– Sell
-20,100
Closed -$58K – 10035
2020
Q1 		$58K Buy
+20,100
New +$69.5K ﹤0.01% 9603
2019
Q3 		– Sell
-15,600
Closed -$60K – 10086
2019
Q2 		$60K Sell
15,600
-17,500
-53% -$77.2K ﹤0.01% 9794
2019
Q1 		$125K Buy
+33,100
New +$117K ﹤0.01% 8155

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jeff Yass's ADMA Position: Q2 2026 in Review

Jeff Yass reduced its ADMA Biologics (ADMA) stake by 33% in Q2 2026, selling an estimated $3.05M and leaving 686,922 shares worth $5.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4347.

Jeff Yass first reported a position in ADMA in Q1 2015 and has held it in 32 quarters since. The position peaked at $9.2M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Jeff Yass held 686,922 shares of ADMA Biologics worth $5.75M as of Q2 2026.
  • Jeff Yass sold 334,682 ADMA Biologics shares in Q2 2026, an estimated $3.05M.
  • ADMA Biologics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4347 holding.
  • Jeff Yass first reported a position in ADMA Biologics in Q1 2015 and has held it in 32 quarters since.
  • Jeff Yass's ADMA Biologics position peaked at $9.2M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.